Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc

Bioconjugate Chemistry

Volumn 10, Issue 3, 1999, Pages 447-453

  Kim, In S ^a   Yoo, Tae M ^a   Kobayashi, Hisataka ^a   Kim, Meyoung Kon ^a   Le, Nhat ^a   Wang, Q C ^a   Pastan, Ira ^a   Carrasquillo, Jorge A ^a   Paik, Chang H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLATION; BLOOD; CHEMICAL MODIFICATION; MAMMALS; MONOCLONAL ANTIBODIES; SULFUR COMPOUNDS;

ACYLATIONS; ANTIBODY-FRAGMENT; BACKGROUND RATIO; GLYCOLATES; INTERLEUKIN2 (IL2); ISO-ELECTRIC POINTS; MURINE MONOCLONAL ANTIBODY; NUDE MICE; TUMOR UPTAKE; VARIABLE REGIONS;

TUMORS;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0033137010     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc980129m     Document Type: Article

References (29)

1. Wolf, R. E., and Breisford, W. G. (1988) Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 31, 729-735
2. Nakanishi, K., Taniguchi, Y., and Ohta, Y. (1991) Increased soluble interleukin-2 receptor levels in autoimmune thyroid disease. Acta Endocrinol. 125, 253-258.
3. Anasetti, C., Hansen, J. A., Waldmann, T. A., Appelbaum, F. R., Davis, J., Deeg, H. J., Doney, K., Martin, P. J., Nash, R., Storb, R., Sullivan, K. M., Witherspoon, R. P., Binger, M.-H., Chizzonite, R., Hakimi, J., Mould, D., Satoh, H., and Light, S. E. (1994) Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 84, 1320-1327.
4. Kay, N. E., Burton, J., Wagner, D., and Nelson, D. L. (1988) The malignant B cell from B-chronic lymphocytic leukemia patients release Tac-soluble interleukin-2 receptors. Blood 72, 447-450.
5. Richards, J., Mick, R., Latta, J. M., Daly, K., Ratain, M. J., Vardiman, J. W., and Colomb, H. M. (1990) Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood 76, 1941-1945.
6. Motoi, T., Uchiyama, T., Hori, T., Itoh, K., Uchino, H., and Ueda, R. (1989) Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood 74, 1052-1057.
7. Ambrosetti, A., Semenzato, G., Prior, M., Chilosi, M., Vinante, F., Vincenzi, C., Zanotti, R., Trentin, L., Portuese, A., Menestrina, F., Perona, G., Agostini, C., and Todeschini, G. (1989) Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. Br. J. Haematol. 73, 181-186.
8. Webber, K. O., Reiter, Y., Brinkmann, U., Kreitman, R., and Pastan, I. (1995) Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analogue. Mol. Immunol. 32, 249-258.
9. Webber, K. O., Kreitman, R. J., and Pastan, I. (1995) Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors. Cancer Res. 55, 318-323
10. 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin-2 alpha receptor-positive tumor xenografts. Cancer Res. 55, 5323-5329.
11. Yoo, T. M., Chang, H. K., Choi, C. W., Webber, K. O., Le, N., Sood, V. K., Carrasquillo, J. A., Eckelman, W. C., Pastan, I., and Paik, C. H. (1997) Radiolabeling of anti-Tac disulfide-stabilized Fv fragment with Tc-99m and its evaluation in athymic mice with tumor xenografts. J. Nucl. Med. 38, 294-300.
12. 67Ga-labeled anti-Tac dsFv fragment. Bioconjugate Chem. 8, 365-369.
13. Maack, T., Park, C. H., and Camargo, M. J. F. (1992) in Renal filtration, transport, and metabolism of proteins. The Kidney: Physiology and Pathophysiology (D. W. Seldin and G. Giebisch, Eds.) 2nd ed., pp 3005-3038, Raven Press, Ltd., New York.
14. Sumpio, B. E., and Maack, T. (1982) Kinetics, competition, and selectivity of tubular absorption of proteins. Am. J. Physiol. 243, F379-F392.
15. Hammond, P. J., Wade, A. F., Gwilliam, M. E., Peters, A. M., Myers, M. J., Gilbey, S. G., Bloom, S. R., and Calam, J. (1993) Amino acid infusion blocks renal tubular uptake of an indium-labeled somatostatin analogue. Br. J. Cancer 67, 1437-1439.
16. 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur. J. Nucl. Med. 22, 608-616.
17. Morgensen, C. E., and Solling, K. (1977) Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand. J. Clin. Lab. Invest. 37, 477-486.
18. Morgensen, C. E., Vittinghus, E., and Solling, K. (1979) Abnormal albumin excretion after two provocative renal tests in diabetes: physical exercise and lysine injection. Kidney Int. 16, 385-393.
19. Rustom, R., Maltby, P., Grime, J. S., Stockdale, H. R., Critchley, M., and Bone, J. M. (1992) Effects of lysine infusion on the renal metabolism of aprotinin (Trasylol) in man. Clin. Sci. 83, 295-299.
20. 99mTc-labeled anti-Tac dsFv. Cancer Res. 56, 3788-3795.
21. Kim, I. S., Yoo, T. M., Kobayashi, H., Kim, M.-K, Le, N., Han, E. S., Wang, Q.-C, Pastan, I., Carrasquillo, J. A., and Paik, C. H. (1997) Acylation with glycolate loweres pI of dsFv and reduces renal uptake of its Tc-99m label (Abstract). J. Labeled Compd. Radiopharm. 15, 422-424.
22. Fritzberg, A. R., Kasina, S., Eshima, D., and Johnson, D. L. (1986) Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement. J. Nucl. Med. 27, 111-116.
23. Visser, G. W. M., Gerretsen, M., Herscheid, J. D. M., Snow, G. B., and van Dongen, G. (1993) Labeling of monoclonal antibodies with Rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J. Nucl. Med. 34, 1953-1963.
24. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77-89.
25. 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the a subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG. Cancer Res. 57, 1955-1961.
26. Lundblad, R. L. (1991) in The modification of lysine. Chemical reagents for protein modification (R. L. Lundblad, Ed.) 2nd ed., pp 129-171, CRC Press, Boca Raton, FL.
27. Tarburton, J. P., Halpern, S. E., Hagan, P. L., Sudora, E., Chen, A., Fridman, D. M., and Phaff, A. E. (1990) Effect of acetylation on monoclonal antibody ZCE-025 Fab': distribution in normal and tumor-bearing mice. J. Biol. Response Mod. 9, 221-230.
28. Fagnani, R., Halpern, S., and Hagan, M. (1995) Altered pharmacokinetic and tumor localization properties of Fab' fragments of a murine monoclonal anti-CEA antibody by covalent modification with low molecular weight dextran. Nucl. Med. Commun. 16, 362-369.
29. Kobayashi, H., Le, N., Kim, I.-S, Kim, M.-K., Pie, J.-E., Drumm, D., Paik, D. S., Waldmann, T. A., Paik, C. H., and Carrasquillo, J. A. (1999) The Pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 69, 422-430.